| 28.96 0.34 (1.19%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.43  |
1-year : | 35.79 |
| Resists | First : | 29.48 |
Second : | 30.64 |
| Pivot price | 28.71 |
|||
| Supports | First : | 27.59 | Second : | 22.95 |
| MAs | MA(5) : | 28.35  |
MA(20) : | 28.78 |
| MA(100) : | 30.84 |
MA(250) : | 32.93 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 33.6 |
D(3) : | 25.7 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 40.71 | Low : | 27.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMCR ] has closed below upper band by 37.3%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 29.46 - 29.58 | 29.58 - 29.69 |
| Low: | 28.27 - 28.4 | 28.4 - 28.52 |
| Close: | 28.75 - 28.96 | 28.96 - 29.15 |
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Wed, 10 Jun 2026
The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why - simplywall.st
Tue, 02 Jun 2026
IMCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Mon, 01 Jun 2026
Assessing Immunocore Holdings (IMCR) Valuation After New Brenetafusp Data At The 2026 ASCO Meeting - Yahoo Finance
Sun, 31 May 2026
Immunocore Reports Promising Phase 1 Data for Brenetafusp in Heavily Pretreated Advanced Melanoma at ASCO 2026 - Quiver Quantitative
Fri, 22 May 2026
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Fri, 15 May 2026
Vestal Point, Ryan Wilder disclose 2.77M ADS stake in Immunocore (IMCR) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 104.4 (%) |
| Shares Short | 8,970 (K) |
| Shares Short P.Month | 9,780 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.51 |
| Profit Margin | -6.7 % |
| Operating Margin | 6.8 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -7.2 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 2.61 |
| Sales Per Share | 8.11 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 150 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | 59 (M) |
| PE Ratio | -51.72 |
| PEG Ratio | 0 |
| Price to Book value | 3.85 |
| Price to Sales | 3.56 |
| Price to Cash Flow | -59.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|